Evaxion Biotech A/S (NASDAQ:EVAX) Stock Price Up 3.6%

Evaxion Biotech A/S (NASDAQ:EVAX)’s stock price rose 3.6% on Friday . The company traded as high as $1.17 and last traded at $1.14. Approximately 97,603 shares changed hands during mid-day trading, a decline of 66% from the average daily volume of 290,582 shares. The stock had previously closed at $1.10.

Evaxion Biotech A/S Price Performance

The company has a market capitalization of $31.77 million, a P/E ratio of -1.16 and a beta of 0.35. The stock’s fifty day simple moving average is $0.82 and its 200-day simple moving average is $1.15. The company has a debt-to-equity ratio of 3.95, a current ratio of 2.81 and a quick ratio of 2.81.

Evaxion Biotech A/S (NASDAQ:EVAX) last posted its quarterly earnings data on Tuesday, August 22nd. The company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.01. On average, equities analysts forecast that Evaxion Biotech A/S will post -0.82 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Evaxion Biotech A/S

Large investors have recently made changes to their positions in the business. Susquehanna International Group LLP raised its position in shares of Evaxion Biotech A/S by 185.4% during the first quarter. Susquehanna International Group LLP now owns 118,722 shares of the company’s stock valued at $134,000 after buying an additional 77,122 shares during the last quarter. JPMorgan Chase & Co. acquired a new position in shares of Evaxion Biotech A/S during the second quarter valued at about $38,000. AE Wealth Management LLC acquired a new position in shares of Evaxion Biotech A/S during the third quarter valued at about $41,000. Finally, Moloney Securities Asset Management LLC acquired a new position in shares of Evaxion Biotech A/S during the first quarter valued at about $41,000. Institutional investors and hedge funds own 0.58% of the company’s stock.

About Evaxion Biotech A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase 1/2a trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers.